BDX - Fundamentals Are The Key For Investors Considering Embecta Stock

2024-07-11 08:48:22 ET

Summary

• Embecta Corp., a spinoff from Becton Dickinson, shows signs of turning around, despite expected earnings declines in fiscal 2024 and 2025.
• This major player in diabetes management, has a history of over 100 years and serves over 30 million people in more than 100 countries.
• Embecta's management team has the experience and expertise to lead the company to increasing profitability, but I'm not expecting much from the share price in the next year.

Investment thesis

Just over two years ago, Becton, Dickinson and Company ( BDX ) spun off its Diabetes Care business into a new company, Embecta Corp. ( EMBC ). It hasn’t been a satisfying story so far:

The decline is not a surprise for those who look at its fundamentals, especially its net income chart. However, there are signs management is now turning the company around, but that will take some time. For fiscal 2024, which ends on September 30, earnings are expected to be down almost 24%. For fiscal 2025, analysts expect another earnings decline of 0.66%....

For further details see: